In a recent interview with CURE®, a medical oncologist from the Dana-Farber Cancer Institute discussed why it’s important for patients with CLL, regardless of their treatment plans, to keep up on vaccinations and maintain a regular cancer screening schedule.
Janice and Rex Cowden sat down for an interview to discuss how to navigate a cancer diagnosis as a couple, and that communication is not only the key to a better cancer journey but a better marriage.
In a recent interview with CURE®, a medical oncologist from the Dana-Farber Cancer Institute in Boston discussed how the addition of Copiktra to a three-drug chemotherapy combination improved outcomes in patients with CLL, with more than half achieving complete remission.
In an interview with CURE®, Dr. Lawrence An discusses how expressive writing can be a tool to reduce stress in patients with cancer.
It's easy to get lost in the statistics of survivorship, but it's important for newly diagnosed patients with cancer to remember that they are not a statistic.
In a recent trial, the addition of chemotherapy to endocrine therapy showed clinical benefit in premenopausal women with lymph node-positive, HR-positive, HER2-negative breast cancer.
Street artist James Cochran gives CURE® an inside look at his newest project: a piece of art he created by applying 50,000 small dots of paint to a canvas using a lab pipette. It will be displayed in the Institute of Cancer Research’s Centre for Cancer Drug Discovery as a symbol of the creativity and commitment of the scientists who work every day to eradicate cancer.
In an interview with CURE®, a Waldenstrom’s macroglobulinemia expert discusses the long-term benefits of the targeted combination of Imbruvica and Rituxan.
Imbruvica treatment in patients with chronic lymphocytic leukemia whose disease expressed a certain mutation elicited sustained efficacy over a median follow-up of four years, according to data from a long-term analysis.
In an interview with CURE®, Dr. Jan A. Burger discusses how the results of two phase 3 studies could help redefine what constitutes as low or high risk in patients with CLL or SLL.
In an interview with CURE®, lead study investigator Dr. John Mascarenhas discusses what the results of the phase 2 IMbark study could mean for the future of patients with myelofibrosis.
The research process for pancreatic cancer is long and difficult, but a new method of clinical trials is looking to adapt to a growing field and find ways to speed up research without losing efficiency.
While the current field of prostate cancer research is experiencing an era of “warp speed developments,” perhaps the most exciting option on the horizon is theranostics, according to Dr. Phillip J. Koo.
Often, patients with cancer will come into contact with only a handful of members of their care team: a primary care physician or oncologist, perhaps a nurse or two. But as Dr. Phillip J. Koo explained, it helps to view the cancer care team – including those who a patient may never see – with a wider lens.
The field of theranostics is growing, and its impact could change the future of prostate cancer treatment. CURE® discusses this potential with a theranostics expert.
Theranostics, or the method of using one radioactive drug to diagnose a malignancy and a second radioactive drug to treat that cancer, is gaining in popularity in the treatment of prostate cancer.
Anxiety is a natural part of the cancer journey, but if it isn't addressed then it can become a major challenge to treatment and recovery.
Caregivers for geriatric patients with cancer are vital members of a patient's care and support system, but often don't get the recognition they deserve.
A new report from the Cancer Support Community shows that extra attention is needed from patient providers to address financial toxicity.
In order to create a better treatment landscape for geriatric patients with cancer, patients need to be involved in the process in order to shape personalized interventions.
Heather Badt, CSC’s Executive Director of the Research & Training Institute, recently shared her personal perspective as a former patient and caregiver with CURE® and expanded on how those who care for loved ones with cancer often face their own unique challenges and require specialized resources themselves
To gain a better understanding of the issues faced by geriatric patients with cancer, and to determine how much of a role nutrition plays in outcomes, Dr. Grant Williams, a geriatrician oncologist and assistant professor at the University of Alabama, Birmingham, worked with colleagues to create a patient-reported assessment tool that bridges the knowledge gap in this patient population.
Nutrition is a vital aspect for patients with cancer, and malnutrition is a concern that must be tracked through the cancer journey.
Doctor turned patient with cancer, Dr. Dan Tran, discusses how research and new medicine can help your hang onto hope during the cancer journey.
Dr. Dan Tran discusses his stage 4 lung cancer diagnosis at age 30, and how he has managed the shift from doctor to the patient with cancer.
Follicular lymphoma treatment options are changing, and according to one expert, immunotherapy could become a major part of therapy sequencing.
Dr. Kami J. Maddocks discusses the importance of effective treatments for patients with aggressive follicular lymphoma and the treatment challenges they face.
Cancer-treatment induced dry mouth can lead to several severe health issues. Here, Dr. Randy Kimple discusses how the side effect can lead to dental health issues, as well as other health consequences including pneumonia.
Emily Whitehead’s family details her journey with cancer and how advocating for their daughter led to Emily’s extraordinary CAR-T cell therapy treatment.
